Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Joseph Saseen to Hydroxymethylglutaryl-CoA Reductase Inhibitors

This is a "connection" page, showing publications Joseph Saseen has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.

 
Connection Strength
  
 
 
4.437
  
  1. Tunoa JA, Billups SJ, Lowe RN, Saseen JJ. Early impact of the 2018 AHA/ACC/multisociety cholesterol guideline on lipid monitoring after statin initiation. J Clin Lipidol. 2020 Nov - Dec; 14(6):784-790.
    View in: PubMed
    Score: 0.510
  2. Wiggins BS, Lamprecht DG, Page RL, Saseen JJ. Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications. Am J Cardiovasc Drugs. 2017 Oct; 17(5):375-389.
    View in: PubMed
    Score: 0.415
  3. Phillips E, Saseen JJ. Current Controversies With Recent Cholesterol Treatment Guidelines. J Pharm Pract. 2016 Feb; 29(1):15-25.
    View in: PubMed
    Score: 0.365
  4. Zupec JF, Marrs JC, Saseen JJ. Evaluation of Statin Prescribing for Secondary Prevention in Primary Care Following New Guideline Recommendations. Ann Pharmacother. 2016 Jan; 50(1):17-21.
    View in: PubMed
    Score: 0.361
  5. Tuchscherer RM, Nair K, Ghushchyan V, Saseen JJ. Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. Am J Cardiovasc Drugs. 2015 Feb; 15(1):27-34.
    View in: PubMed
    Score: 0.345
  6. Lowe RN, Vande Griend JP, Saseen JJ. Statins for the primary prevention of cardiovascular disease in the elderly. Consult Pharm. 2015 Jan; 30(1):20-30.
    View in: PubMed
    Score: 0.343
  7. Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy. 2008 May; 28(5):553-61.
    View in: PubMed
    Score: 0.216
  8. Marrs JC, Saseen JJ. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients. Pharmacotherapy. 2008 May; 28(5):562-9.
    View in: PubMed
    Score: 0.216
  9. Saseen J, Tweed E, Crawford P. Clinical inquiries. What are effective medication combinations for dyslipidemia? J Fam Pract. 2006 Jan; 55(1):70-2.
    View in: PubMed
    Score: 0.184
  10. Daugird AJ, Crowell K, Saseen J. Clinical inquiries. Do statins cause myopathy? J Fam Pract. 2003 Dec; 52(12):973-7.
    View in: PubMed
    Score: 0.159
  11. Lamprecht DG, Saseen JJ, Shaw PB. Clinical conundrums involving statin drug-drug interactions. Prog Cardiovasc Dis. 2022 Nov-Dec; 75:83-89.
    View in: PubMed
    Score: 0.148
  12. Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022 Jul-Aug; 16(4):361-375.
    View in: PubMed
    Score: 0.144
  13. Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, Orringer CE, Saseen JJ, Smith SC, Sperling LS, Virani SS. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
    View in: PubMed
    Score: 0.137
  14. Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021 08; 35(4):853-864.
    View in: PubMed
    Score: 0.132
  15. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):3168-3209.
    View in: PubMed
    Score: 0.112
  16. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):e285-e350.
    View in: PubMed
    Score: 0.112
  17. Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016 11 22; 134(21):e468-e495.
    View in: PubMed
    Score: 0.097
  18. Graham JH, Sanchez RJ, Saseen JJ, Mallya UG, Panaccio MP, Evans MA. Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. J Clin Lipidol. 2017 Jan - Feb; 11(1):70-79.e1.
    View in: PubMed
    Score: 0.097
  19. Wiggins BS, Saseen JJ, Morris PB. Gemfibrozil in Combination with Statins-Is It Really Contraindicated? Curr Atheroscler Rep. 2016 Apr; 18(4):18.
    View in: PubMed
    Score: 0.094
  20. Alford JC, Saseen JJ, Allen RR, Nair KV. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Pharmacotherapy. 2012 Jul; 32(7):623-30.
    View in: PubMed
    Score: 0.071
  21. Bittner V, Linnebur SA, Dixon DL, Forman DE, Green AR, Jacobson TA, Orkaby AR, Saseen JJ, Virani SS. Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society. J Clin Lipidol. 2025 Mar-Apr; 19(2):215-237.
    View in: PubMed
    Score: 0.044
  22. Hess CN, Daffron A, Nehler MR, Morrison JT, Buchanan CE, Szarek M, Anderson VE, Cannon CP, Hsia J, Saseen JJ, Bonaca MP. Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2024 Jun 25; 83(25):2658-2670.
    View in: PubMed
    Score: 0.041
  23. Valuck RJ, Williams SA, MacArthur M, Saseen JJ, Nair KV, McCollum M, Ensor JE. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther. 2003 Nov; 25(11):2936-57.
    View in: PubMed
    Score: 0.040
  24. Robinson JG, Jayanna MB, Brown AS, Aspry K, Orringer C, Gill EA, Goldberg A, Jones LK, Maki K, Dixon DL, Saseen JJ, Soffer D. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. J Clin Lipidol. 2019 Jul - Aug; 13(4):525-537.
    View in: PubMed
    Score: 0.029
  25. Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, Underberg JA. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol. 2017 Jul - Aug; 11(4):880-890.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)